FRα Antibody Guides Targeted Therapy Decisions for Ovarian Cancer
1. Literature Information
This research highlights FRα as a pivotal target in ovarian cancer and validates FRα antibodybased IHC as a critical tool to select patients for FRαtargeted ADC therapy.
2. Research Background
FRα is overexpressed in 80–90% of highgrade serous ovarian cancers. It enhances folate uptake, activates JAK/STAT3 and MAPK/ERK signaling, and drives aggressive tumor behavior.
3. Research Approach
IHC using FRαspecific recombinant antibodies evaluates expression intensity and percentage in FFPE specimens. High expression predicts favorable response to ADCs.
4. Research Outcomes
· FRα overexpression correlates with advanced stage and poor prognosis.
· FRα ADCs effectively target platinumresistant ovarian cancer.
· Intratumoral heterogeneity requires careful sampling and interpretation.
· Standardized IHC conditions ensure diagnostic accuracy.
5. Product Empowerment
ANT BIO PTE. LTD. provides FRα Recombinant Rabbit mAb (S0B2388).
· Highly specific for human FRα with minimal background.
· Validated for IHC, WB, flow cytometry, and IF.
· Recombinant design eliminates hybridoma drift.
· Essential for pathology diagnosis and companion testing.
6. Brand Mission
ANT BIO PTE. LTD. provides highquality life science reagents to advance ovarian cancer research and therapy. Our subbrands support every stage from basic research to clinical diagnostics.
7. Related Product List
|
Product Name |
Catalog No. |
Type |
Core Application |
|
FRα Recombinant Rabbit mAb |
Recombinant Rabbit mAb |
Ovarian cancer IHC, targeted therapy guidance |
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
